According to a research report "Single Cell Sequencing Market by Product (Reagents & Kits, Platforms, Software), Workflow (Presequencing), Service (Sample Preparation, Bioinformatics), Sequencing (scRNA, scDNA), Application (Research, Diagnostic), End User - Global Forecast to 2030" published by MarketsandMarkets, The single-cell sequencing market is expected to reach USD 3.46 billion by 2030, up from USD 1.95 billion in 2025, at a CAGR of 12.2% during the forecast period.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=244864213
The growth in the global single-cell sequencing market is driven by the increasing use of this sequencing technique by researchers and clinicians to better understand diseases at the cellular level. In clinical and translational research, the technology helps identify patient-specific genetic changes and supports the development of precision medicines. Advancements in sequencing technologies have made single-cell analysis faster, more accurate, and more affordable. At the same time, there is increasing demand for detailed, high-resolution data that traditional bulk sequencing cannot provide. New approaches like multi-omics and spatial transcriptomics are also becoming more common, allowing scientists to study gene activity in the context of tissue structure. These trends create strong opportunities for companies to offer specialized kits, software, and complete solutions for cancer research, neuroscience, and drug development. Companies that respond to these needs will likely benefit as the market expands.
By product type, the pre-sequencing consumables segment accounted for the largest market share in 2024.
Based on product type, the single-cell sequencing market is segmented into consumables, instruments, and software. The consumables segment is further sub-segmented into pre-sequencing and sequencing consumables. The pre-sequencing consumables segment held the largest share of the global single-cell sequencing consumables market in 2024. The large share of this segment is attributed to the recurring demand for consumables required for the pre-sequencing stage of the single-cell sequencing procedure. With the growing use of single-cell sequencing in clinical research, diagnostics, and translational studies, the demand for reliable and high-performance consumables continues to rise. Moreover, most leading companies generate over 80% of their single-cell product revenue from consumables, underlining their central role in the workflow. This trend is expected to continue as labs expand adoption of single-cell sequencing technology across oncology, neurology, and immunology research.
By sequencing type, the single-cell transcriptome (RNA) sequencing segment accounted for the largest market share in 2024.
By sequencing type, the single-cell sequencing market is divided into single-cell transcriptome (RNA) sequencing, single-cell genome (DNA) sequencing, single-cell ATAC sequencing, and other single-cell sequencing techniques. In 2024, single-cell transcriptome sequencing held the largest share in the single-cell sequencing market. This is due to its wide application in understanding gene expression at the single-cell level, across research and clinical settings. One of the key uses of scRNA-seq is to build high-resolution cellular atlases of different organisms, which serve as valuable resources for studying health and disease. By capturing data on mRNA expression, protein markers, cell-to-cell interactions, and spatial context, scRNA-seq helps uncover the complexity of tissues and disease mechanisms. As adoption increases, companies invest in RNA-specific consumables like targeted assays and optimized kits, while service providers expand their scRNA-seq offerings to attract more customers. These efforts further support the large share of transcriptome sequencing in the market.
By region, North America accounted for the largest market share in 2024.
The single-cell sequencing market is segmented into North America, Europe, Asia Pacific (APAC), Latin America (LATAM), the Middle East, and Africa. In 2024, North America accounted for the most significant global single-cell sequencing market share, driven by its well-established healthcare infrastructure, substantial investments in life sciences research, and the strong presence of leading biotechnology and pharmaceutical companies. The region demonstrates a high adoption rate of single-cell sequencing technologies such as scRNAseq and scDNAseq, which are increasingly utilized for cancer & neurological disease research, genetic disorder detection, and diagnostic applications. Additionally, favorable regulatory policies, robust government and private sector funding for molecular diagnostics, and the growing emphasis on precision medicine continue to support market growth. This well-established ecosystem offers key market players opportunities to expand their single-cell sequencing portfolios, strengthen collaborations with academic and clinical research institutions, and develop innovative diagnostic solutions tailored to evolving healthcare needs.
Key players in the single-cell sequencing market include 10x Genomics (US), Illumina Inc. (US), Thermo Fisher Scientific Inc. (US), BD (US), QIAGEN (Netherlands), and Danaher (US), among others
